CAR T-cell therapies have shown substantial efficacy in several haematological conditions and hold the potential for transformative benefits in certain other indications.

However, the complex journey to deliver CAR T-cell therapies to patients and associated operational and capacity-related needs can lead to suboptimal access to and use of these therapies.

Despite the launch of this modality in the U.S. in 2017 and in EU in 2018, barriers to patient access remain.

This webinar is intended to engage in dialogue multiple experts to identify key areas of focus to improve CAR T-cell therapy delivery and discuss an initial set of actions that could be tailored to specific country or regional needs.

This webinar will include external experts as well as Institute staff. This webinar is ideal for:

• Providers
• Healthcare policymakers
• Patient advocates
• Pharma
• And all areas of the life sciences industry

Agenda:

• Welcome and introductions
• Moderated discussion among panelists
  1. The current readiness of the CAR T-cell therapy journey in different geographies, from strategy development and patient identification to site designation, initiation, administration, and monitoring
  2. Key barriers and best practices for enhancing the delivery of CAR T-cell therapy
  3. Healthcare policies needed to ensure equitable and timely access to CAR T-cell therapy
• Q&A
• Concluding thoughts